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.2013.01.Abstract Background: This study was designed to mainly evaluate the efﬁcacy and safety of olan-
zapine compared with placebo and ondansetron for prevention of postoperative nausea and vom-
iting in patients undergoing breast surgeries.
Methods: Eighty two female patients scheduled for breast surgeries were randomly assigned to four
test groups received placebo or single oral dose of olanzapine 5 mg (OL5) or 10 mg (OL10) or
ondansetron 16 mg (ON16) before induction of anesthesia by 4 h for olanzapine and 1 h for ondan-
setron. All patients were monitored for 24 h. Emetic episodes and nausea occurrence were the pri-
mary outcome in this study. Secondary endpoint was the complete response (CR) (without nausea
and vomiting, no rescue therapy) for the acute (0–2 h) and late (2–24 h) periods.
Results: Need for rescue antiemetics showed signiﬁcant reduction (P< 0.05) for all groups in com-
parison with placebo. Number needed to be treated (NNT) improved on increasing dose of
olanzapine from 5 mg to 10 mg for prevention of both nausea (48%) and vomiting (36%) in com-
parison to placebo.
In the 0–2 h postoperative time interval, complete response (CR) rates were insigniﬁcant (P= 0.48,lestine Madina Road, P.O.
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90 M. Ibrahim et al.P= 0.11) for olanzapine 5 mg and 10 mg when compared to placebo; and signiﬁcant for ondanse-
tron 16 mg (P= 0.04). For the 2–24 h interval after surgery, CR rates were signiﬁcant for OL5,
OL10, and ON16 (P= 0.02, P= 0.005, P= 0.007) when compared to placebo. On comparing
both olanzapine doses with ondansetron 16 mg during 0–2 h and 2–24 h study periods, there were
no signiﬁcant differences.
Conclusion: Olanzapine can be used safely and effectively for prophylaxis against PONV especially
for late postoperative periods.
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Postoperative nausea and vomiting (PONV) is the most fre-
quent side effect after anesthesia, occurring in 30%of unselected
inpatients and up to 70% of ‘‘high-risk’’ inpatients during the
24 h after emergence [1]. Postoperative nausea and vomiting
can result in morbidity like wound dehiscence, bleeding, pul-
monary aspiration of gastric contents, ﬂuid and electrolyte dis-
turbances, delayed hospital discharge, unexpected hospital
admission, and decreased patient satisfaction [2]. Nausea, retch-
ing and vomiting are among the most common postoperative
complications and can occur after general, regional or local
anesthesia [3]. PONV is thought to be multifactorial in origin,
involving anesthetic, surgical, and individual risk factors [4].
Some of these factors which affect the incidence of PONV in-
clude age, sex, history of previous PONV or motion sickness,
smoking, surgical procedure, duration of surgery and anesthe-
sia, and anxiety [2]. General anesthesia using volatile anesthetics
is associated with an average incidence of postoperative nausea
and vomiting (PONV) ranging between 20% and 30% [2].
Some operations are reported to be associated with a higher
incidence of PONV than others. These include plastic (breast
augmentation), ophthalmologic (strabismus repair), ENT-den-
tal, gynaecologic, laparascopic (sterilisation), genitourinary,
orthopaedic surgery (shoulder procedures), mastectomies and
lumpectomies [5]. Traditional antiemetics (droperidol and met-
oclopramide) are frequently used for the prevention of PONV
during the ﬁrst 24 h after anesthesia [6].
Olanzapine, an atypical antipsychotic agent of the thi-
obenzodiazepine class, blocks multiple neurotransmitter recep-
tors, including dopaminergic (D1, D2, D3, D4), serotonergic
(5-HT2A, 5-HT2C, 5-HT3, 5-HT6), adrenergic (alpha1),
histaminic (H1), and muscarinic (m1, m2, m3, m4) receptors
[7]. By virtue of acting on a number of key receptor sites, olan-
zapine as a single agent has a distinct advantage over combina-
tions of various antiemetics by improving compliance and
reducing drug interactions [8].
The main objective of this study was to evaluate, in a ran-
domized manner, the comparative efﬁcacy of single oral dose
of atypical antipsychotic olanzapine (5 mg and 10 mg) and oral
ondansetron hydrochloride (16 mg) for the prophylaxis of
PONV in patients undergoing elective breast surgery under
general anesthesia. Patients were observed for 24 h postopera-
tively. More speciﬁcally, we determined whether there were
statistically signiﬁcant differences in the incidence and severity
of nausea and vomiting (including retching), proportion of pa-
tients with complete response (no nausea, vomiting and no
need for rescue antiemetic) and the number of rescue antie-
metic doses needed to treat emetic episodes. Also, undesirableside effects (including sedation, anxiety, restlessness, and
abnormal muscle movements, and headache) were recorded.
1.1. Patient and method
After approval of our facility clinical research Ethics Commit-
tee, a written informed consent was obtained from all partici-
pants. Eighty two female patients scheduled for breast
surgeries (mastectomy, tumor biopsy, reductive mastoplasty
and other plastic surgery) were studied (mean age 39 ± 9 years).
All patients were ASA physical status I or II. Patients were ex-
cluded from study if they had preexisting nausea, vomiting or
motion sickness, receiving opioids or drugs with known antie-
metic properties in the 24 h before surgery, history of esophageal
reﬂux or opioid or alcohol abuse; had a serum creatinine greater
than 2.0 mg/dl; had a serum alanine aminotransferase (ALT) or
aspartate transaminase (AST) greater than two times the upper
limits of normal and patients with body weight twice their ideal
body weight. Patients were allowed to eat solids until midnight
on the day prior to surgery and to drink clear liquids until 3 h
before the scheduled start of surgery. Patients were randomly
allocated to one of four groups received placebo or single oral
dose of olanzapine 5 mg (OL5) or 10 mg (OL10) or ondansetron
16 mg (ON16). All patients received 1–2 mg midazolam as pre-
medication. Olanzepine groups (OL5 and OL10) received olan-
zapine 5 mg and 10 mg respectively 4 h before induction of
anesthesia while ondansetron group (ON16) received ondanse-
tron 16 mg 1 h before induction of anesthesia orally with sip
water. To ensure blindness placebo drug was given in OL5
and OL10 groups 1 h before induction and 4 h before induction
inON16. Placebo group of patients received sugar pills 4 and 1 h
before induction. After a patient was assigned to a treatment
group, the assignment was recorded and placed in a sealed enve-
lope by a person not involved in the study. A pharmacist, who
was also not involved in the study, prepared the study medica-
tions and sealed it in an envelope. The appropriate patient enve-
lope according to previous random assignment was sent to a
nurse who was responsible for administering the drugs to pa-
tients. A nurse or a physician, who were blinded to the patient
treatment groups gave the study drugs and recorded preopera-
tive and postoperative data.
Induction of anesthesia was the same for all groups using
propofol 2-3 mg kg1, rocuronium 1 mg kg1 for intubation
and maintenance of muscle relaxation. After preoxygenation
for 3 min and endotracheal intubation was done. Orogastric
tube was introduced and suction was applied to empty the
stomach from air and other contents. Maintenance with an
opioid fentanyl 2–5 ug kg1, nitrous oxide and oxygen, and
sevoﬂurane volatile anesthetic as needed. Reversal of
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50 lg kg1 neostigmine and 8 lg kg1 glycopyrrolate. The
nasogastric tube was suctioned and then removed before tra-
cheal extubation.
During anesthesia standard monitoring (electrocardiogram,
noninvasive blood pressure, ETco2, and pulse oximetry) was
used.
Pre-emptive analgesia was done before patient recovery by
Lornoxicam (ZEFOR) 8 mg intravenous and Paracetamol
(PerfalganR) one gram by intravenous infusion.
Postoperative pain relief was provided by IV ZEFOR was
given for postoperative analgesia q 8 h and IV Paracetamol
1 g at 8 h intervals. All patients were kept for monitoring in
the PACU for 2 h. After that 2 h the patients moved to the sur-
gical ward to be monitored and watched at 6th, 12th, 18th, and
24th h by a nurse or a physician, who were blinded to the pa-
tient treatment groups.
Emetic episodes and nausea occurrence were the primary
outcome in this study. An emetic episode was deﬁned as vom-
iting or retching or any combination that occurred in rapid se-
quence of less than 1 min between episodes. Nausea was
deﬁned using a categorical 11-point linear whole number scale
for which 0 represented ‘‘no nausea’’ and 10 represented ‘‘nau-
sea as bad as it can possibly be’’. Secondary endpoint was the
complete response (CR) (without nausea and vomiting, no res-
cue therapy) for the acute (0–2 h) and late (2–24 h) periods.
Need for rescue antiemetic, the intensity of postoperative
pain, opioid pain therapy, and any adverse events (including
sedation, anxiety, restlessness, and abnormal muscle move-
ments, and headache) were recorded. 11-point scale in which 0
was no pain at all and 10 represented the worst pain imaginable
was used to assess postoperative pain during the study period.
Rescue antiemetic was allowed at any time on patient re-
quest, after three emetic episodes, for nausea lasting at least
15 min, or according to physician assessment. The patient
was considered a treatment failure if rescue antiemetic was
required.
Patient’s safety was evaluated including vital signs taken
just prior to ingestion of study drug, immediately before induc-
tion of anesthesia, every 15 min intraoperatively, upon entry to
and every 15 min in the post-anesthesia care unit (PACU) for
2 h, and 24 h postoperatively. Laboratory tests (complete
blood count, chemistry, renal and liver function tests) were
done preoperatively and again at 24 h postoperatively.1.2. Statistical analysis
The study was designed to enroll 80 patients to achieve a power
of 80% to detect for a 40% difference in the incidence of nausea
or vomiting with alpha level of 0.05. The Cochran–Mantel–
Haenszel test was used to compare each olanzepine groups
and ondansetron group with the placebo group with regard to
(1) the proportion of patients with no emetic episodes and no
nausea over the 24-h study (2) interdose comparisons between
olanzapine 5 mg, 10 mg doses and ondansetron 16 mg dose with
respect to the proportion of patients reporting no emesis and the
proportion reporting no nausea, (3) analysis of efﬁcacy (com-
plete response rates) among strata. Number needed to be treated
(NNT) was calculated as the reciprocal of the absolute risk
reduction. The percentage of patients with complete response
for acute period and delayed period was calculated separatelyin test groups and control group. TheX2 test was utilized to ana-
lyze complete response and to compare the relative frequency of
post treatment abnormal laboratory values. Fisher’s exact test
was used to make pair-wise comparisons of the ondansetron
and olanzapine groups with the placebo group with regard to
adverse events.
2. Results
Eighty two patients were included in the study. There were no
signiﬁcant differences in patients’ characteristics between treat-
ment groups, including relation of surgery time with stage of
menstrual cycle. The mean duration of anesthesia and duration
of operation were not different. Also, no signiﬁcant differences
were noted among groups with respect to surgery type (Table 1).
Olanzapine and ondansetron doses were signiﬁcantly better
than placebo in preventing both emesis and nausea (Table 2)
during the 24-h observation period. Also olanzapine and
ondansetron doses were also more effective than placebo in
preventing the need for rescue antiemetics. Fifty-seven percent
of the patients in the placebo group required rescue during the
24 h following surgery compared with 48%, 37%, and 38% of
those receiving olanzapine 5 mg, 10 mg, and ondansetron
16 mg (P= 0.04, P= 0.002, and P= 0.001), respectively.
When comparisons were made for all patients, the olanzapine
10 mg and ondansetron 16-mg dose were better than the 5 mg
dose of olanzapine at preventing nausea and emesis but lack
signiﬁcance (P> 0.05). NNT improved on increasing dose
of olanzapine from 5 mg to 10 mg by 48% and 36% regarding
to prevention of nausea and vomiting respectively (Table 2).
2.1. Complete response
Compared with placebo, a trend in the proportion of patients
with a complete response (CR) was observed with increasing
dose of olanzapine from 5 mg to 10 mg across the 24-h study
interval. In the 0–2 h postoperative time interval, CR rates
were placebo, 58%; olanzapine 5 mg, 73% (P = 0.48); olanza-
pine 10 mg, 80% (P = 0.11); and ondansetron 16 mg, 90%
(P= 0.04) (Fig. 1). For the 2–24 h interval after surgery, CR
rates were signiﬁcant for OL5, OL10, and ON16 (P = 0.02,
P = 0.005, P = 0.007) when compared to placebo. On com-
paring both olanzapine doses with ondansetron during study
period 0–2 h, ondansetron 16 mg was better but lack signiﬁ-
cance (P> 0.05). Olanzapine 5 mg and 10 mg were better than
ondansteron 16 mg but lack signiﬁcance (P = 0.68, P = 0.59)
throughout 2–24 h study period.
Both treatments were well tolerated. There were no signiﬁ-
cant differences between treatment groups regarding mean vi-
tal signs recorded intraoperatively or postoperatively. Also no
signiﬁcant differences were recorded in treatment groups’ lab-
oratory values when compared with those obtained preopera-
tively. The overall incidence of adverse events was similar
across all treatment groups. The frequency of adverse affects,
including sedation, anxiety, restlessness, and abnormal muscle
movements, and headache were evaluated. The most common
potentially drug-related adverse event was headache, which oc-
curred insigniﬁcantly more in (6%) ondansetron-treated pa-
tients compared with olanzapine treated patients (3%). None
of the headaches required speciﬁc interventions. Arrhythmia
was not reported in all treatment groups.
Table 1 Patient characteristics.
Placebo (n= 21) OL5 (n= 21) OL10 (n= 20) ON16 (n= 20)
Age (year) 42 ± 13 41 ± 14 43 ± 12 42 ± 12
BMI (kg/m2) 25 ± 5 26 ± 4 27 ± 4 26 ± 5
ASA physical status
I 12 10 12 11
II 9 11 8 9
Number of days since last menstrual cycle
0–8 (menstrual) 5 5 4 5
9–16 (follicular) 7 8 7 6
<16 (luteal) 7 7 7 7
No menses 2 1 2 2
Smokers 4 5 5 3
Type of surgery
Mastectomy 5 4 6 4
Tumor biopsy 6 5 6 6
Reductive mastoplasty 6 6 4 6
Other plastic surgery 4 6 4 4
Duration of anesthesia (min) 107 ± 53 103 ± 49 110 ± 48 105 ± 51
Duration of operation (min) 81 ± 50 78 ± 52 82 ± 55 87 ± 49
Intraoperative fentanyl (lg/kg) 1.8 ± 03 2.0 ± 0.1 2.1 ± 0.1 1.9 ± 2
Table 2 Efﬁcacy analysis during the whole 24-h.
Placebo (n= 21) OL5 (n= 21) OL10 (n= 20) ON16 (n= 20)
% NNT % NNT % NNT
Early outcome 0–2 h
No emesis 12/21 16/21 5.2 17/20 3.1 18/20 3.0
57 76 85* 90*
No nausea 10/21 14/21 5.2 16/20 3.0 17/20 2.4
47 66 80 85*
Late outcome 2–24 h
No emesis 8/21 13/21 4.2 16/20 2.4 15/20 2.7
(38) (62) (80)* (75)*
No nausea 5/21 9/21 5.2 13/20 2.6 12/20 2.7
(23.8) (42.8) (65)* (60)*
NNT= number needed to treat.
* P< .05 compared with placebo.
Figure 1 Percent of patients experiencing complete response (no nausea and emesis) during the 2-h, 2–6 h, 6–12 h and 12–24 h study
periods for all treatment groups. \P< 0.05 in comparison to placebo.
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No serious adverse events were reported. In all the volunteers
drowsiness was reported as an adverse event, which was attrib-
uted to the pharmacological action of olanzapine. In one vol-
unteer, elevation in their liver function tests (LFTs) was
reported at the end of the study safety evaluation.
Approximately 45% of the patients in this study received
postoperative opioids (meperidine), and there were no signiﬁ-
cant differences with a better tolerance in olanzapine patients
(placebo_43%, olanzapine 5 mg_39%, olanzapine 10 mg_ 36%,
and ondansetron 16 mg_46%).
3. Discussion
In this study we evaluated the antiemetic efﬁcacy, safety, and
use of prophylactic olanzapine and compared it with placebo
and ondansetron, a ‘‘gold standard’’ antiemetic, in high risk
of postoperative vomiting breast surgery [9] in high risk female
patients [10]. Olanzapine and ondansetron doses were signiﬁ-
cantly better than placebo in preventing both emesis and nau-
sea. NNT and percentage of CR improved on increasing dose
of olanzapine from 5 mg to 10 mg regarding to prevention of
nausea and vomiting. Also we found that both the olanzapine
5 mg and 10 mg were well tolerated and no serious adverse
events were reported.
Olanzapine’s activity at multiple receptors––particularly at
the D2, 5-HT2c, and 5-HT3 receptors, which appear to be in-
volved in nausea and emesis––suggests that it may have signiﬁ-
cant antiemetic properties [11]. Phase I study made sure the
maximum tolerated dose of olanzapine which is 5 mg per day
for the 2 days prior to chemotherapy and 10 mg per day for
7 days post-chemotherapy and revealed effectiveness in preven-
tion of late nausea and vomiting [12]. In phase II trial of olanza-
pine [13] in combination with granisetron and dexamethasone
for prevention of chemotherapy induced nausea and vomiting
(CINV), the combination therapy proved to be highly effective
in controlling acute and delayed CINV in patients receiving
highly and moderately emetogenic chemotherapy.
Ondansetron is a potent, highly selective 5HT3 receptor-
antagonist. The mechanisms of action in post-operative nausea
and vomiting are not known but there may be common path-
ways with cytotoxic induced nausea and vomiting. Following
oral dosing with ondansetron, peak plasma concentrations
are achieved in approximately 1.5 h [14].
Tramer et al. [15] assessed the efﬁcacy of ondansetron, com-
pared with placebo or no treatment, for the prevention of post-
operative nausea and vomiting (PONV); to test dose-response
evidence; to identify the optimal dose for oral and intravenous
routes; and to investigate the potential of ondansetron for
toxic effects in the surgical setting, and they found that ondan-
setron 16 mg was regarded as the optimal ﬁxed oral dose tested
in these trials. Our study results indicate that all doses of olan-
zapine (5 mg and 10 mg) and ondansetron 16 mg were effective
when compared with placebo at preventing both emesis and
nausea for the 24 h observation postoperatively. Interdose
comparisons showed that 10 mg of olanzapine was signiﬁ-
cantly better than 5 mg for the complete control of emesis.
In the 24-h prevention of nausea and vomiting, olanzapine
10 mg and ondansetron 16 mg was signiﬁcantly superior to
olanzapine 5 mg. However, in order to assess the clinical sig-
niﬁcance of a statistically signiﬁcant ﬁnding, some method ormeasure must be identiﬁed. One method is the NNT [16] which
is deﬁned as the reciprocal of the absolute risk reduction. The
NNT thus identiﬁes the number of patients who must be trea-
ted in order to prevent one adverse event. Thus the number-
needed-to-treat is a useful estimate of clinical relevance of
treatment effect. For the entire study population, the NNT
for no emesis are 4.2, 2.4, and 2.7, and for no nausea they
are 5.2, 2.6, and 2.7 for 5 mg, 10 mg of olanzapine, and
16 mg of ondansetron, respectively. These ﬁgures are better
than those documented by Rust and Cohen [17] where the
NNT to prevent nausea and vomiting with 16 mg oral ondan-
setron up to the 48 h compared with placebo were 5.9 and 4.4,
respectively. Also, our results regarding the percentage of no
emesis and no nausea were 75% and 60% whereas European
study results of Rust and Cohen [17] showed 54% and 42%
respectively. This difference between our study and Rust and
Cohen may be due to differences in study population (Arab
and European) and observation period (24 h in our study
48 h in Rust and Cohen study) as efﬁcacy of ondansetron lasts
up to 24 h only [25].
In the present study we found that olanzapine 10 mg was
comparable to ondansetron 16 mg regarding absence of events
(no nausea and vomiting) and NNT. CR rates in our study
showed better but insigniﬁcant differences between olanzapine
5 mg and 10 mg and placebo during 0–2 h study period
(p= 0.48 and 0.11 respectively), but ondansetron 16 mg
showed signiﬁcance (p= 0.04) in comparison with placebo
in the same period. The rest of study period (2–24 h) showed
signiﬁcant differences between the all study drugs and placebo.
In the other hand, olanzapine 5 mg and 10 mg did not show
signiﬁcance when compared with ondansetron 16 mg with
superiority of olanzapine 10 mg dose. In our study increasing
the dose of olanzapine from 5 to 10 mg led to a decrease of
more than 20% in the NNT (i.e. an improvement) for the pre-
vention of both nausea (48%) and vomiting (36%) in compar-
ison to placebo.
Based on the preset deﬁnition of clinical relevance of anti-
emetic efﬁcacy (number-needed-to-treat < 5) [18], Tramer
et al. [15] considered an increase in efﬁcacy of at least 20%
as clinically relevant. Thus a decrease of number-needed-to-
treat from 5 to 4 (i.e. treating 4 patients instead of ﬁve for
one to beneﬁt) was regarded as clinically relevant
improvement.
Previous studies [11–13] on olanzapine efﬁcacy and safety
in controlling nausea and vomiting were performed in patients
receiving highly and moderately emetogenic chemotherapy.
Tan et al. [7] concluded that olanzapine can improve the com-
plete response of delayed nausea and vomiting in patients
receiving the highly or moderately emetogenic chemotherapy
comparing with the standard therapy of antiemesis.
In two phase II studies, olanzapine demonstrated effective
prevention of both acute and delayed chemotherapy induced
nausea and vomiting (CINV) in patients receiving highly or
moderately emetogenic chemotherapy [12,19].
In one small phase III study [20], compared olanzapine with
aprepitant both combined with dexamethasone and palonose-
tron in the prevention of CINV in highly emetogenic chemo-
therapy and concluded that olanzapine regimen (O) showed
comparable results to the aprepitant regimen (A) in regard
to acute [100% (O) versus 90% (A)], delayed [77% (O) versus
73% (A)] and overall [77% (O) versus 73% (A)] CR.
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a single dose of dexamethasone and a single dose of palones-
terone was very effective at controlling acute and delayed
CINV in patients receiving highly emetogenic chemotherapy.
Our results in this study is consistent with the previous tri-
als on olanzapine use to control CINV taking in consideration
that (1) Acute periods in those trials were considered up to
24 h from the start of chemotherapy due to longer course of
chemotherapy while acute period of PONV settings was con-
sidered 0–2 h. (2) Combination therapy used in these trials
aided in better control of N&V during acute period.
In our study, we found better pain tolerance in olanzapine
receiving patients without signiﬁcance that coincide with small
study on cancer patients and they concluded that olanzapine
may reduce opioid requirements and be ‘‘opioid sparing’’ in
cancer patients with uncontrolled pain who also have cognitive
impairment or anxiety [21].
In this study, for the doses given of olanzapine 5 mg and
10 mg were not associated with signiﬁcant sedation, weight
gain, or induction of signiﬁcant hyperglycemia that is consis-
tent with Rudolph et al. [11] who used 10 mg daily for 4 days,
and concluded that these effects have been associated with
olanzapine given for longer periods of time. Previous studies
have shown that extrapyramidal side effects of olanzapine
are signiﬁcantly reduced compared to other antipsychotics
[22,23].
The trial arms in the study were blinded in spite of different
olanzapine and ondansetron pharmacokinetics that affect time
of drug administration. Oral Administration, monotherapy of
olanzapine is well absorbed and reaches peak concentrations in
approximately 5 h following an oral dose. Its half-life ranges
from 21 to 54 h (mean of 30 h) [24].
The single dose ondansetron bioavailability is approxi-
mately 56% when administered orally with time to peak plas-
ma concentrations occurring at approximately 1.7 h. Despite
the plasma half-life of approximately 3–4 h, efﬁcacy is for
24 h, indicating that the therapeutic action of ondansetron ex-
ceeds the half-life of the drug [25].
Our study design has several limitations, including studying
olanzapine efﬁcacy in patients with prior history of PONV or
motion sickness, a lack of cost effectiveness analysis and to ex-
tend the observation period to 48 h or 72 h postoperative.
Our study strength was in the comparison of olanzapine
with placebo and the gold standard antiemetic, ondansetron,
in its best studied dose.
Future investigations may explore the efﬁcacy of olanza-
pine with adding combination of rapid onset and short acting
antiemetic, e.g. propofol may give more satisfactory results in
acute postoperative period.
We concluded that olanzapine can be used safely and effec-
tively for prophylaxis against PONV especially high risk surgi-
cal procedure under general anesthesia. It was more effective in
late postoperative period and olanzapine 10 mg dose was com-
parable to the ondansetron 16 mg that was described as ‘‘opti-
mal single oral dose’’ [15].
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